Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-07-23
2010-02-23
Shukla, Ram R (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S145100
Reexamination Certificate
active
07666417
ABSTRACT:
The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders.
REFERENCES:
patent: 5698195 (1997-12-01), Le et al.
patent: 6262244 (2001-07-01), Houchins et al.
patent: 6458350 (2002-10-01), Cosman et al.
patent: 6653447 (2003-11-01), Cosman et al.
patent: 6737249 (2004-05-01), Adams et al.
patent: 2002/0187151 (2002-12-01), Raulet et al.
patent: 2003/0095965 (2003-05-01), Van Beneden et al.
patent: 2003/0165835 (2003-09-01), Spies et al.
patent: 2003/0171280 (2003-09-01), Soderstrom
patent: 2004/0115198 (2004-06-01), Spies et al.
patent: 2005/0233391 (2005-10-01), Spies et al.
patent: 2006/0280755 (2006-12-01), Baron et al.
patent: 2007/0077241 (2007-04-01), Spies et al.
patent: 2007/0248607 (2007-10-01), Spies et al.
patent: WO 98/19167 (1998-05-01), None
patent: WO 01/71005 (2001-09-01), None
patent: WO 02/068615 (2002-09-01), None
patent: WO 03029436 (2003-04-01), None
patent: WO 03/089616 (2003-10-01), None
Schrambach et al., PLoS ONE. Jun. 2007 132:e518.
Diefenbach et al., (2002) Nat Immunol. 3(12):1142-9.
Goronzy et al., Curr Opin Rheumatol. May 2004;16(3):212-7.
Gratama et al., Cytometry. Apr. 15, 2002;50(2):92-101.
Cardozo et al., Diabetologia. Feb. 2003;46(2):255-66.
Martinelli et al., Gastroenterology. Jun. 1996;110(6):1791-802.
Marshall et al., J Autoimmun. Feb. 2004;22(1):1-11.
Luzza et al., FEMS Immunol Med Microbiol. Jun. 1999;24(2):233-8.
Bergman et al., “Gastric Autoimmunity”, pp. 1-19, In Heliobacter pylori Physiology and Genetics, Mobley et al., eds., ASM Press, 2001.
Saegusa et al., J Immunol. Aug. 15, 2000;165(4):2251-7.
Janeway et al., Immunobiology, 5th Ed., Garland Science, pp. 94-105 (2001).
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 79: 1979-1 983, Mar. 1982.
Colman P. M., Research in Immunology, 145:33-36, 1994.
Ziwei Huang, Pharmacol Ther. Jun. 2000;86(3):201-15.
Whitty et al., Chem. Biol. Apr. 1999;6(4):R107-18.
S.J. van Deventer, Best Pract Res Clin Gastroenterol. Feb. 2003;17(1):119-30.
Strom et al., Therapeutic Immunology edited by Austen et al., Blackwell Science, Cambridge, MA, 1996, pp. 451-456.
Sakai et al., Gastroenterology, Jun. 1998;114(6):1237-43.
Bauer et al., “Activation of NK cells and T cells by NKG2D, a receptor for stress-induced MICA,”Science, 285(5428)727-729, 1999.
Chapman et al., “CD11b+CD28-CD4+ human T cells: activation requirements and association with HLA-DR alleles,”J. Immunol, 157(11):4771-4780, 1996.
Das et al., “MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function,”Immunity, 15:83-93, 2001.
Feldman et al., “Perspectives of arterial gene therapy for the prevention of restenosis,”Cardiovasc. Res., 32:194-207, 1996.
Groh et al., “Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation,”Nature, 419:734-738, 2002.
Groh et al., “Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB,”Proc. Natl. Acad. Sci., USA, 96:6879-6884, 1999.
Groh et al., “Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium,”Proc. Natl. Acad. Sci., USA, 93:12445-12450, 1996.
Groh et al., “Costimulation of CD8αβT cells by NKG2D via engagement by MIC induced on virus-infected cells,”Nature Immunology, 2(3):255-260, 2001.
Groh et al., “Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells,”Science, 279:1737-1740, 1998.
Ivashiv, “Cytokine expression and cell activation in inflammatory arthritis,”Adv Immunol, 63:337-376, 1996.
Klavins et al., “Advances in biological markers for cancer,”Ann Clin Lab Sci, 13:275-280, 1983.
Klimiuk et al., “Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent,”Clin Immunol, 90:65-78, 1999.
Krause et al., “Rheumatoid arthritis synoviocyte survival is dependent on stat3,”J. lmmunol, 169:6610-6616, 2002.
Kurowska et al., “Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-xLand Bcl-2l,”J Immunol, 169:1760-1767, 2002.
Lanier et al., “Turning on natural killer cells,”J Exp Med, 191(8):1259-1262, 2000.
Lanier, “On guard-activating NK cell receptors,”Nat lmmunol, 2:23-27, 2001.
Li et al., “Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA,”Nat Immunol, 2(5):443-451, 2001.
Martens et al., “Expansion of unusual CD4+ T cells in severe rheumatoid arthritis,”Arthritis and Rheumatism, 40(6):1106-1114, 1997.
McInnes et al., “The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis,”Nat Med, 2(2):175-182, 1996.
McInnes et al., “Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis,”Nat Med, 3(2):189-195, 1997.
Mingari et al., “Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations,”Proc. Natl. Acad. Sci., USA, 93:12433-12438, 1996.
Moser et al., “CD94-NKG2A receptors regulate antiviral CD8+ T cell receptors,”Nature Immunology, 3(2):189-195, 2002.
Muller-Ladner et al., “Molecular biology of cartilage and bone destruction,”Curr Opin Rheumatol, 10:212, 1998.
Namekawa et al., “Functional subsets of DC4 T cells in rheumatoid synovitis,”Arthritis and Rheumatism, 41(12):2108-2116, 1998.
Park et al., “Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4′CD28- T cells,”Eur J Immunol, 27:1082-1090, 1997.
Pohl et al., “Present value of tumor markers in clinic,”Cancer Detect Prevent, 6:7-20, 1983.
Ravetech et al., “Immune inhibitory receptors,”Science, 290:84-89, 2000.
Roberts et al., “Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment,”J Immunol, 167:5527, 2001.
Schmidt et al., “CD4+ CD7-CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity,”J. Clin Invest, 97:2027-2037, 1996.
Sikorska et al., “Clinical applications of carcinoembryonic antigen,”Cancer Detect Prevent, 12:321-355, 1988.
Snyder et al., “Formation of the killer Ig-like receptor repertoire on CD4+CD28 null T cells ,”J. Immunol, 168:3839-3846, 2002.
Speiser et al., “CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from health donors and melanoma patients,”Eur J Immunol, 29:1990-1999, 1999.
Steinle et al., “Interactions of human NKG2D with its ligands MICA, MICB and homologs of the mouse RAE-1 protein family,”Immunogenetics, 53(4):279-287, 2001.
Sultzeanu et al., “Human and cancer associated antigens: present status and implications for immunodiagnosis,”Adv Cancer Res, 44:1-42, 1985.
Tieng et al., “Binding ofEscherichia coliadhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA,”Proc. Natl. Acad. Sci., USA, 99(5):2977-2982, 2002.
Vallejo et al., “Clonality and longevity of CD4+CD28 null T cells are associated with defects in apoptotic pathways,”J Immunol, 165:6301-6307, 2000.
Viriji et al., “Tumor markers in cancer d
Spies Thomas
Spies Veronika
Fred Hutchinson Cancer Research Center
Fulbright & Jaworski L.L.P.
Shukla Ram R
Skelding Zachary
LandOfFree
Methods and compositions for treating autoimmune diseases or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating autoimmune diseases or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating autoimmune diseases or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4229601